Anavex Stockholders,

The future direction of the Company is in your hands. We urge you to vote “FOR” Anavex’s six highly qualified, independent director nominees on the WHITE universal proxy card today for the following three reasons:

Protect the future of Anavex. Vote “FOR” all six Anavex nominees on the WHITE proxy card.

How to Vote

The 2026 Annual Meeting of Stockholders is scheduled to be held on September 24, 2026. Stockholders of record as of July 31, 2026 are entitled to vote.

Vote today “FOR” all six Anavex director nominees on the WHITE proxy card. Your vote is important, no matter how many shares you own.

If you have questions or need assistance voting your shares, please contact:
‍
Innisfree M&A Incorporated
500 Fifth Avenue, 21st Floor
New York, NY 10110

Stockholders may call toll-free at (877) 750-0831. Brokers, banks and other nominees may call collect at (212) 750-5833.

Online

Go to the website shown on your WHITE proxy card. You will be required to provide the unique control number printed on your proxy card.

Phone

Use any touch-tone telephone to call the telephone number shown on your WHITE proxy card. You will be required to provide the unique control number printed on your proxy card.

Mail

Mark, sign and date your WHITE proxy card and return it in the postage-paid envelope we have provided.

CLINICAL PROGRESS & REGULATORY EXECUTION

The Board and management team are focused on advancing oral blarcamesine across three CNS indications while strengthening engagement with the FDA to establish a clear, data-driven path forward.
Alzheimer’s Disease

Advancing toward FDA alignment on the U.S. clinical development program and Phase 3 study design.

  • Submitted all Alzheimer’s clinical trial data to its newly opened Investigational New Drug application (IND) to support planned FDA discussions regarding the U.S. clinical development program and design of a Phase 3 study (ANAVEX2-73-AD-005) for an Alzheimer’s indication.
  • Advancing two foundational clinical pharmacology studies under the IND, including an ADME study and a DDI study with the first participant visit completed in the ADME study and the last participant in the DDI study expected to complete last visit by the end of September.
  • Incorporating EMA CHMP feedback on the Marketing Authorization Application and FDA Type C meeting feedback to position completed studies within the overall U.S. clinical development plan.
  • Received scientific advice from the EMA on the Phase 3 study (ANAVEX2-73-AD-005) protocol design and is incorporating this feedback into its planned discussions with the FDA, with the goal of achieving a strong, well-aligned study design across both regulatory agencies.
  • Refreshed and streamlined the Scientific Advisory Board to a focused group of Alzheimer’s disease key opinion leaders and treating physicians, who have confirmed their continued interest in supporting the Company’s efforts. Their input will be critical in designing a practical and clear protocol, helping guide the development of blarcamesine from a physician and patient perspective.
Rett Syndrome

Moving forward with adult Phase 3 study while pursuing expansion to pediatric patients.

  • Oral blarcamesine has received FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations.
  • Aligned with the FDA on a Phase 3 protocol for adult patients and is moving forward with the study.
  • Requested a formal meeting with the FDA to discuss the potential inclusion of pediatric patients in the clinical development program.
Fragile X Syndrome

Preparing to initiate the clinical program.

  • Oral blarcamesine has received FDA Orphan Drug Designation.
  • Planning an IND submission for September 2026 to support initiation of the Fragile X clinical program.
Focused on Creating Long-Term Value
The Special Committee of the Board moved quickly to appoint experienced interim leadership, refresh the Board with highly qualified independent nominees and maintain a focus on advancing programs with the greatest potential to create long-term stockholder value.

While Anavex is executing a defined clinical and regulatory strategy, PVG has not articulated a comparable plan for advancing the Company’s pipeline or engaging with the FDA.
THE CHOICE IS CLEAR: ANAVEX VS. PVG
Anavex PVG
✓Clear strategy for advancing blarcamesine across three CNS indications.
✗No disclosed strategic plan for the Company.
✓Active FDA engagement and regulatory execution.
✗No articulated regulatory roadmap.
✓Two new highly qualified independent nominees.
✗Slate concentrated primarily in investment management and equity research.
✓Significant life sciences, clinical and governance expertise.
✗Only one nominee with a clinical medical background.
✓Focused on long-term stockholder value creation.
✗No stated plan for creating stockholder value.

The choice is clear. Anavex is executing a defined strategy to advance its pipeline and create stockholder value. PVG is seeking control of the company without presenting stockholders with a clear plan for the future.

THE RIGHT BOARD FOR ANAVEX’S NEXT PHASE

Anavex’s six nominees bring the experience, independence and expertise needed to oversee a clinical-stage biotechnology company during a critical period of execution and regulatory engagement.

If Anavex’s nominees are elected, half of the Board will have been refreshed since the beginning of 2026, and all Board members will be independent.

Meet the six highly qualified nominees standing for election at the 2026 Annual Meeting:

Dr. Jiong Ma

Independent Chair
General Partner at Phoenix Venture Partners with more than 30 years of experience investing in, building and scaling technology and life sciences companies globally. Dr. Ma has served on the Anavex Board since 2021 and brings deep financial, transactional and capital markets expertise and significant board experience, including serving as Lead Independent Director of SES AI Corporation, as a former director of Chavant Capital Acquisition Corporation and Mobix Labs, and as a board member across multiple Phoenix Venture Partners and Braemar Energy Ventures portfolio companies.

Dr. Peter Donhauser

Physician and clinical research leader with more than 20 years of experience in integrated medical care, clinical trial oversight and private practice leadership. Dr. Donhauser has served on the Anavex Board since 2017 and brings valuable clinical and patient-centered expertise, including research experience across more than 12 Phase III trials conducted with leading global pharmaceutical companies.

Dr. Axel Paeger

CEO of AMEOS Group, one of Europe’s leading healthcare providers, with more than 30 years of clinical, operational and executive leadership experience. Dr. Paeger has served on the Anavex Board since 2026 and previously served on the Supervisory Board of Ascom Group, bringing public company governance experience alongside deep healthcare operating expertise.

Mr. Gautam Patel

New Independent Nominee
Managing Director and Investment Committee member at Tarsadia Investments with more than 30 years of corporate finance, investment management and board leadership experience. Mr. Patel brings extensive public and private company board experience, including service on the boards of Amneal Pharmaceuticals and Spectrum Brands Holdings, where he chairs the Audit Committee, as well as private company boards including Kashiv Biosciences, Asana Biosciences, LERETA and AIONX Antimicrobial Technologies.

Dr. Adrian Senderowicz

New Independent Nominee
President and Founder of Oncology Drug Development, LLC and an accomplished pharmaceutical executive and physician-scientist with more than 30 years of clinical and regulatory leadership experience. Dr. Senderowicz brings board and scientific advisory experience, including service on the Board of Puma Biotechnology, where he chairs the Research and Development Committee, prior service on the Board of Step Pharma, and scientific advisory roles at Triana Biomedicines and Stelexis BioSciences.

Dr. Claus van der Velden

Managing Director and Chief Financial Officer of NetCologne GmbH with more than two decades of experience leading finance, governance and enterprise oversight functions for publicly traded and technology-driven companies. Dr. van der Velden has served on the Anavex Board since 2018 and brings accounting, executive financial, governance and capital allocation expertise to the Board.
WHY PVG’S NOMINEES ARE NOT THE RIGHT CHOICE
Seeking Control Without a Plan

PVG and Patrick Adams collectively own approximately 0.35% of Anavex’s outstanding shares yet are seeking control of the Board without paying stockholders a premium.

At a critical time for Anavex, PVG’s own proxy materials provide no meaningful discussion of a strategy or operating plan for advancing the Company’s pipeline or creating long-term stockholder value.

The Wrong Experience for a Clinical-Stage Biopharmaceutical Company

Anavex is at a critical inflection point and urgently focused on advancing oral blarcamesine across Alzheimer’s disease, Rett syndrome and Fragile X syndrome while engaging with the FDA on critical regulatory pathways.

Yet PVG has not presented stockholders with a clear alternative plan, timeline or regulatory strategy, and based on our review, PVG’s nominees do not have the necessary experience to advance our clinical and regulatory objectives:

For a clinical-stage biotechnology company facing complex regulatory and development decisions, these are significant gaps.

Stockholders should ask: Why replace a Board that has taken decisive action with a dissident slate that has not articulated a roadmap for the Company’s future?

Frequently Asked Questions

Why is the Executive Committee of the Anavex Board recommending stockholders vote “FOR” all six Anavex nominees on the WHITE proxy card?

The Executive Committee of Anavex’s Board believes Anavex’s nominees possess the experience, independence and expertise required to oversee a clinical-stage biotechnology company at a critical point in its development.

The Board and management team are executing a defined strategy focused on advancing oral blarcamesine across Alzheimer’s disease, Rett syndrome and Fragile X syndrome, while maintaining active engagement with the FDA regarding future regulatory pathways.

The Executive Committee of the Anavex Board believes electing the Company’s nominees will provide continuity, stability and oversight as Anavex continues executing on this strategy and pursuing long-term stockholder value creation.

What is at stake at the 2026 Annual Meeting?

Stockholders are being asked to elect six directors to the Board of Anavex, four incumbent independent directors and two newly nominated independent candidates.

The outcome of the election will determine who oversees the Company’s strategic direction, regulatory engagement and clinical development programs at an important stage of execution.

The Executive Committee of Anavex’s Board believes it is important that Anavex remain focused on advancing its pipeline and engaging constructively with regulators while pursuing opportunities to create long-term stockholder value.

Why does the Executive Committee of Anavex’s Board oppose PVG’s director nominees?

Neither PVG nor its nominees have presented stockholders with a detailed strategic plan for advancing Anavex’s clinical programs, engaging with the FDA or creating long-term stockholder value.

The Executive Committee of Anavex’s Board believes that replacing Anavex’s experienced and refreshed Board would create unnecessary risk at a critical time for the Company.

The Executive Committee of Anavex’s Board further believes that Anavex’s nominees offer a stronger combination of life sciences, clinical, financial, governance and public company experience.

What experience do Anavex’s nominees bring to the Board?

Anavex’s six nominees collectively bring expertise spanning biotechnology, medicine, clinical research, pharmaceutical development, finance, capital markets, corporate governance and executive leadership.

If elected, half of the Board will have been refreshed since the beginning of 2026, and all directors will be independent.

The Executive Committee of the Anavex Board believes this combination of relevant expertise and independence positions Anavex to effectively oversee the Company’s next phase of execution.

How is Anavex advancing blarcamesine?

Anavex is pursuing development of oral blarcamesine across three CNS indications: Alzheimer’s disease, Rett syndrome and Fragile X syndrome.

The Company has submitted all data from its Alzheimer’s clinical trials to its newly opened FDA Investigational New Drug (IND) application to support planned FDA discussions regarding the U.S. clinical development program and the design of a Phase 3 study (ANAVEX2-73-AD-005) for an Alzheimer’s indication. Additionally, the company has aligned with the FDA on a Phase 3 protocol for adult Rett syndrome patients and is moving forward with the study. The company has also requested a formal FDA meeting to discuss the potential inclusion of pediatric patients in the Rett syndrome clinical development program and is planning an IND submission for Fragile X syndrome in September 2026 to support initiation of the clinical program.

The Executive Committee of the Anavex Board believes these actions demonstrate continued progress toward advancing the Company’s pipeline.

What happens if Anavex’s nominees are elected?

If elected, the Board intends to continue executing the Company’s clinical and regulatory strategy, maintaining engagement with the FDA and focusing resources on programs that offer the potential to create long-term stockholder value.

The Executive Committee of the Anavex Board believes continuity of oversight is important as the Company advances its development activities and evaluates future opportunities.

Who is entitled to vote at the 2026 Annual Meeting?

Stockholders who owned Anavex common stock as of the close of business on July 31, 2026 are entitled to vote at the Annual Meeting scheduled for September 24, 2026.

How do I vote my shares?

Stockholders may vote online, by telephone, or by mail. To ensure your vote is counted, please follow the instructions provided on your WHITE proxy card and submit your vote as soon as possible.

Online: Go to the website shown on your WHITE proxy card. You will be required to provide the unique control number printed on your proxy card.

By Phone: Use any touch-tone telephone to call the telephone number shown on your WHITE proxy card. You will be required to provide the unique control number printed on your proxy card.

By Mail: Mark, sign and date your WHITE proxy card and return it in the postage-paid envelope we have provided.  

I hold my shares through a broker or bank. Do I still need to vote?

Yes. 

If your shares are held in a brokerage account (for example, with a firm like Fidelity, Schwab or Robinhood) or through a bank, your broker cannot vote your shares without instructions from you.  

Failure to provide voting instructions will result in your shares not being voted on the election of directors.  

Please follow the voting instructions provided by your broker or bank as soon as possible. If you have questions about how to vote your shares, contact Anavex’s proxy solicitor, Innisfree M&A Incorporated:

Stockholders: (877) 750-0831
Banks and Brokers: (212) 750-5833

Can I change my vote after I have submitted it?

Yes.

Stockholders generally may revoke or change their vote before the closing of the polls at the Annual Meeting by submitting a later-dated proxy card.  Only your latest-dated proxy will be counted.

Who can I contact if I need help voting my shares?

If you have questions or require assistance voting your shares, please contact:
‍
Innisfree M&A Incorporated
500 Fifth Avenue, 21st Floor
New York, NY 10110

Stockholders: (877) 750-0831
Banks and Brokers: (212) 750-5833

RESOURCES

Stockholder 
Letters

September 16, 2026: Letter to Anavex Stockholders
‍
‍August 31, 2026: Letter to Anavex Stockholders
‍
‍August 24, 2026: Letter to Anavex Stockholders
‍
‍August 17, 2026: Letter to Anavex Stockholders
‍
‍August 11, 2026: Letter to Anavex Stockholders
‍
‍August 3, 2026: Letter to Anavex Stockholders

Press
Releases

August 11, 2026: Definitive Proxy Press Release

‍August 3, 2026: Preliminary Proxy Press Release

‍

Filings
‍

Definitive Proxy Statement
© 2026 Anavex Life Sciences Corp. All rights reserved.
Privacy Policy